Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: J Natl Compr Canc Netw. 2011 Nov;9(11):1293–1302. doi: 10.6004/jnccn.2011.0105

Table 2.

Colorectal Cancer Biomarker Tests in Development

Biomarker
Name		 Type of
Specimen
Required		 Type of Test Stage(s)
of Disease		 Intended Use Current
Validation Status		 Commercial
Availability
ColoPrint Fresh,
unfixed
tumor tissue		 Gene expression
profile by
oligonucleotide
array		 II Prognostic
marker
for recurrence risk
in stage II colon
cancer		 Two non-
randomized
validation
studies;64,65 PARSC
trial underway66 		Anticipated
(Agendia)
CTC Peripheral
blood
collected in
preservative
tube		 Immunomagnetic
separation of
epithelial cells
from whole blood		 IV Prognostic
for survival in
patients
with metastatic
colorectal
cancer		 Multiple studies
including meta-
analysis data
and randomized
subset from
==CAIRO2
study67,69 		Multiple
including
CellSearch
System
(Veridex, LLC)
Oncotype
DX Colon
Cancer
Test		 FFPE tumor
tissue		 Gene expression
profile by RT-PCR		 II Prognostic
marker for
recurrence risk
in stage II colon
cancer		 Independent
validation in
randomized
subset from
QUASAR
study;70 second
independent
validation set
presented at 2011
ASCO Annual
Meeting71 		Yes
(Genomic
Health, Inc.)

Abbreviations: CTC, circulating tumor cells; FFPE, formalin-fixed, paraffin-embedded; PARSC, Prospective Analysis of Risk stratification by ColoPrint; RT-PCR, reverse transcriptase-polymerase chain reaction.